Cargando…

Potential Immune Biomarker Candidates and Immune Subtypes of Lung Adenocarcinoma for Developing mRNA Vaccines

mRNA vaccines against cancer have advantages in safety, improved therapeutic efficacy, and large-scale production. Therefore, our purpose is to identify immune biomarkers and to analyze immune status for developing mRNA vaccines and selecting appropriate patients for vaccination. We downloaded clini...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yang, Tan, Huaicheng, Yu, Ting, Chen, Xiaoxuan, Jing, Fangqi, Shi, Huashan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670181/ https://www.ncbi.nlm.nih.gov/pubmed/34917077 http://dx.doi.org/10.3389/fimmu.2021.755401

Ejemplares similares

Identifying tumor antigens and immuno‐subtyping in colon adenocarcinoma to facilitate the development of mRNA vaccine
por: Tan, Huaicheng, et al.
Publicado: (2022)

Comprehensive Analyses of Immune Subtypes of Stomach Adenocarcinoma for mRNA Vaccination
por: You, Weiqiang, et al.
Publicado: (2022)

Dissecting Tumor Antigens and Immune Subtypes of Glioma to Develop mRNA Vaccine
por: Zhong, Hua, et al.
Publicado: (2021)

Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development
por: Lin, Han, et al.
Publicado: (2022)

Recognition of Tumor-Associated Antigens and Immune Subtypes in Glioma for mRNA Vaccine Development
por: Ma, Shuai, et al.
Publicado: (2021)

Recognition of immune-related tumor antigens and immune subtypes for mRNA vaccine development in lung adenocarcinoma
por: Zhao, Deze, et al.
Publicado: (2022)

Identification of Tumor Antigens and Immune Subtypes in Lung Adenocarcinoma for mRNA Vaccine Development
por: Xu, Ran, et al.
Publicado: (2022)

Identification of Immune Subtypes and Candidate mRNA Vaccine Antigens in Small Cell Lung Cancer
por: Wei, Yuanfeng, et al.
Publicado: (2023)

Evaluating distinct KRAS subtypes as potential biomarkers for immune checkpoint inhibitor efficacy in lung adenocarcinoma
por: Wang, Qi, et al.
Publicado: (2023)

Exploitation of tumor antigens and construction of immune subtype classifier for mRNA vaccine development in bladder cancer
por: Zhang, Xin, et al.
Publicado: (2022)

Comparison of Immune Responses Elicited by SARS-CoV-2 mRNA and Recombinant Protein Vaccine Candidates
por: Wu, Yixin, et al.
Publicado: (2022)

The identification of gene signatures in patients with extranodal NK/T-cell lymphoma from a pair of twins
por: Wang, Yang, et al.
Publicado: (2021)

Influenza Viruses: Innate Immunity and mRNA Vaccines
por: Lee, SangJoon, et al.
Publicado: (2021)

A Novel Artificial Neural Network Prognostic Model Based on a Cancer-Associated Fibroblast Activation Score System in Hepatocellular Carcinoma
por: Luo, Yiqiao, et al.
Publicado: (2022)

Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development
por: Huang, Xing, et al.
Publicado: (2021)

Humoral and cellular immunity to SARS-COV-2 after vaccination with mRNA vaccines in PLWH with discordant immune response. Influence of the vaccine administered
por: López-Cortés, Luis F., et al.
Publicado: (2023)

Identification of lncRNAs associated with T cells as potential biomarkers and therapeutic targets in lung adenocarcinoma
por: SUN, LU, et al.
Publicado: (2023)

Integration of Immune Cell Populations, mRNA-Seq, and CpG Methylation to Better Predict Humoral Immunity to Influenza Vaccination: Dependence of mRNA-Seq/CpG Methylation on Immune Cell Populations
por: Zimmermann, Michael T., et al.
Publicado: (2017)

Machine learning reveals two heterogeneous subtypes to assist immune therapy based on lipid metabolism in lung adenocarcinoma
por: Gu, Xuyu, et al.
Publicado: (2022)

Identification of tumor antigens and immune landscapes for bladder urothelial carcinoma mRNA vaccine
por: Sun, Zhuolun, et al.
Publicado: (2023)

NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis
por: Liu, Xu-Sheng, et al.
Publicado: (2021)

Mini Review Immunological Consequences of Immunization With COVID-19 mRNA Vaccines: Preliminary Results
por: Lombardi, Andrea, et al.
Publicado: (2021)

Immune Response in Moderate to Critical Breakthrough COVID-19 Infection After mRNA Vaccination
por: Paniskaki, Krystallenia, et al.
Publicado: (2022)

Long Lasting Cellular Immune Response Induced by mRNA Vaccination: Implication for Prevention Strategies
por: Vitiello, Laura, et al.
Publicado: (2022)

Longitudinal monitoring of mRNA-vaccine-induced immunity against SARS-CoV-2
por: Monzon-Posadas, Werner O., et al.
Publicado: (2023)

Corrigendum: NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis
por: Liu, Xu-Sheng, et al.
Publicado: (2021)

Immune responses and disease biomarker long-term changes following COVID-19 mRNA vaccination in a cohort of rheumatic disease patients
por: An, Zesheng, et al.
Publicado: (2023)

Identification of tumor antigens and immune subtypes in lung squamous cell carcinoma for mRNA vaccine development
por: Zhao, Jiaying, et al.
Publicado: (2022)

Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy
por: Li, Ruiyu, et al.
Publicado: (2021)

Immune profiles according to EGFR mutant subtypes and correlation with PD-1/PD-L1 inhibitor therapies in lung adenocarcinoma
por: Koh, Young Wha, et al.
Publicado: (2023)

Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development
por: Huang, Xing, et al.
Publicado: (2021)

Identification of tumor antigens and immune subtypes of glioma for mRNA vaccine development
por: Chen, Zhuohui, et al.
Publicado: (2022)

Analysis of melanoma tumor antigens and immune subtypes for the development of mRNA vaccine
por: Ping, Haiqin, et al.
Publicado: (2022)

Adaptive immune response to BNT162b2 mRNA vaccine in immunocompromised adolescent patients
por: Bader, Guy, et al.
Publicado: (2023)

Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma
por: Sun, Hao, et al.
Publicado: (2020)

RASGRP2 is a potential immune-related biomarker and regulates mitochondrial-dependent apoptosis in lung adenocarcinoma
por: Liu, Yongting, et al.
Publicado: (2023)

Immune Infiltration Subtypes Characterization and Identification of Prognosis-Related lncRNAs in Adenocarcinoma of the Esophagogastric Junction
por: Hu, Xin, et al.
Publicado: (2021)

A single vaccination of nucleoside-modified Rabies mRNA vaccine induces prolonged highly protective immune responses in mice
por: Bai, Shimeng, et al.
Publicado: (2023)

Immunization with a novel mRNA vaccine, TGGT1_216200 mRNA-LNP, prolongs survival time in BALB/c mice against acute toxoplasmosis
por: Zhang, Yizhuo, et al.
Publicado: (2023)

Immune Microenvironment in Glioblastoma Subtypes
por: Chen, Zhihong, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_1sf3123ktf50ldubd0aifg6ukn